SMAD4 and hepatocellular carcinoma: [169] found that overexpression of SMAD2 and SMAD4 was associated with enhanced EMT, which in turn caused a mesenchymal phenotype and increased resistance to doxorubicin and sorafenib in both HCC patients and in vitro model.